Targeted Oncology Therapeutics – Breast Cancers


 TBC201K October 2021 • US$3,850 


The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of breast cancers. This report examines the fifty therapeutic drugs and the biomarkers they utilize.


Targeted Oncology Therapeutics





What You Will Learn

• What is the market share of approved therapeutics?
• What is the global supply picture for targeted therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the major Oncology market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation therapeutics?


Summary of Contents

Executive Summary

The Recombinant Drug Ecosystem

Biological Drug Activity by Region

Biological Oncology Market Leaders

Oncology mAbs: Competitive Considerations

mAbs and Targeted Oncology Therapeutics

Historical Growth of Biologicals

Leading Biological Drug Companies – Activity by Drug & Segment

FDA Approved mAbs Indicated for Oncology (Ado to Bre)

FDA Approved mAbs Indicated for Oncology (Cem to Ipl)

FDA Approved mAbs Indicated for Oncology (Mog to Pol

FDA Approved mAbs Indicated for Oncology (Ram to Tra)

Drugs Indicated for Specific Breast Cancers

Targeting Drugs Approved for Treating Breast Cancers

Monoclonal Antibodies

Tyrosine Kinase Inhibitors

The Addressable Market


Drugs in Development

Leading Breast Cancer Supplier Assessments